These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 22011479)

  • 21. Presence of ultrasound subclinical synovitis and increment of serum vascular endothelial growth factor in a patient with rheumatoid arthritis achieved in sustained clinical remission by treatment with adalimumab and methotrexate.
    Kawashiri SY; Arima K; Suzuki T; Nakashima Y; Horai Y; Okada A; Tamai M; Nakamura H; Kawakami A
    Mod Rheumatol; 2014 Jul; 24(4):681-4. PubMed ID: 24533548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.
    Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ
    Ann Rheum Dis; 2007 Jul; 66(7):921-6. PubMed ID: 17301106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples.
    Smith SL; Eyre S; Yarwood A; Hyrich K; Morgan AW; Wilson AG; Isaacs J; ; Plant D; Barton A
    Arthritis Res Ther; 2015 Dec; 17():359. PubMed ID: 26667261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adenosine Deaminase Gene Polymorphism and Baseline Serum Level of Adenosine Deaminase as a Biomarker of Response to Methotrexate in Rheumatoid Arthritis.
    Gangadharan H; Singh A; Majumder S; Aggarwal A
    J Clin Rheumatol; 2021 Dec; 27(8):e609-e611. PubMed ID: 33044386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study.
    Han BK; Kuzin I; Gaughan JP; Olsen NJ; Bottaro A
    Arthritis Res Ther; 2016 Apr; 18():93. PubMed ID: 27102921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis.
    Finzel S; Kraus S; Figueiredo CP; Regensburger A; Kocijan R; Rech J; Schett G
    Ann Rheum Dis; 2019 Sep; 78(9):1186-1191. PubMed ID: 31142474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modular analysis of peripheral blood gene expression in rheumatoid arthritis captures reproducible gene expression changes in tumor necrosis factor responders.
    Oswald M; Curran ME; Lamberth SL; Townsend RM; Hamilton JD; Chernoff DN; Carulli J; Townsend MJ; Weinblatt ME; Kern M; Pond CM; Lee A; Gregersen PK
    Arthritis Rheumatol; 2015 Feb; 67(2):344-51. PubMed ID: 25371395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.
    Jani M; Chinoy H; Warren RB; Griffiths CE; Plant D; Fu B; Morgan AW; Wilson AG; Isaacs JD; Hyrich K; Barton A;
    Arthritis Rheumatol; 2015 May; 67(8):2011-9. PubMed ID: 26109489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
    Smolen JS; Burmester GR; Combe B; Curtis JR; Hall S; Haraoui B; van Vollenhoven R; Cioffi C; Ecoffet C; Gervitz L; Ionescu L; Peterson L; Fleischmann R
    Lancet; 2016 Dec; 388(10061):2763-2774. PubMed ID: 27863807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes.
    Gabay C; Burmester GR; Strand V; Msihid J; Zilberstein M; Kimura T; van Hoogstraten H; Boklage SH; Sadeh J; Graham NMH; Boyapati A
    Arthritis Res Ther; 2020 Apr; 22(1):70. PubMed ID: 32264972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale.
    Gossec L; Strand V; Proudfoot C; Chen CI; Guillonneau S; Kimura T; van Hoogstraten H; Mangan E; Reaney M
    J Rheumatol; 2019 Oct; 46(10):1259-1267. PubMed ID: 30877216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis.
    Slot O; Brünner N; Locht H; Oxholm P; Stephens RW
    Ann Rheum Dis; 1999 Aug; 58(8):488-92. PubMed ID: 10419867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis.
    Carlson JJ; Ogale S; Dejonckheere F; Sullivan SD
    Value Health; 2015 Mar; 18(2):173-9. PubMed ID: 25773552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study.
    Hirata S; Saito K; Kubo S; Fukuyo S; Mizuno Y; Iwata S; Nawata M; Sawamukai N; Nakano K; Yamaoka K; Tanaka Y
    Arthritis Res Ther; 2013 Sep; 15(5):R135. PubMed ID: 24286472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma MicroRNA Profiles in Patients with Early Rheumatoid Arthritis Responding to Adalimumab plus Methotrexate vs Methotrexate Alone: A Placebo-controlled Clinical Trial.
    Sode J; Krintel SB; Carlsen AL; Hetland ML; Johansen JS; Hørslev-Petersen K; Stengaard-Pedersen K; Ellingsen T; Burton M; Junker P; Østergaard M; Heegaard NHH
    J Rheumatol; 2018 Jan; 45(1):53-61. PubMed ID: 29142030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis.
    Stuhlmüller B; Häupl T; Hernandez MM; Grützkau A; Kuban RJ; Tandon N; Voss JW; Salfeld J; Kinne RW; Burmester GR
    Clin Pharmacol Ther; 2010 Mar; 87(3):311-21. PubMed ID: 20032971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritis.
    Krintel SB; Essioux L; Wool A; Johansen JS; Schreiber E; Zekharya T; Akiva P; Ostergaard M; Hetland ML
    PLoS One; 2012; 7(6):e38539. PubMed ID: 22685579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of adalimumab treatment on endothelial cell activation markers in the skeletal muscle of patients with rheumatoid arthritis.
    Bergström U; Grundtman C; Lundberg IE; Jacobsson LT; Nilsson K; Turesson C
    Clin Exp Rheumatol; 2014; 32(6):883-90. PubMed ID: 25287961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of integrated radiographic data from two long-term, open-label extension studies of adalimumab for the treatment of rheumatoid arthritis.
    Landewé R; Østergaard M; Keystone EC; Florentinus S; Liu S; van der Heijde D
    Arthritis Care Res (Hoboken); 2015 Feb; 67(2):180-6. PubMed ID: 25073879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD39 positive regulatory T cell frequency as a biomarker of treatment response to methotrexate in rheumatoid arthritis.
    Gupta V; Katiyar S; Singh A; Misra R; Aggarwal A
    Int J Rheum Dis; 2018 Aug; 21(8):1548-1556. PubMed ID: 30146748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.